An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Tafenoquine (Primary) ; Chloroquine
- Indications Vivax malaria
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.
- 25 Jan 2016 Planned initiation date changed from 1 Jun 2016 to 1 Sep 2016, as reported by ClinicalTrials.gov.
- 06 Oct 2015 New trial record